Leukotrienes and atherosclerosis

Current Drug Targets

Volumn 11, Issue 7, 2010, Pages 882-887

  Riccioni, Graziano ^a   Bäck, Magnus ^b   Capra, Valérie ^c  

^a University Hospital   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Antileukotrienes; Atherosclerosis; Cardiovascular diseases; Myocardial infarction; Stroke

Indexed keywords

C REACTIVE PROTEIN; CHEMOATTRACTANT; CYSTEINYLDOPA; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PADGEM PROTEIN; THROMBIN;

ARTERIAL WALL THICKNESS; ARTERY CALCIFICATION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; NONHUMAN; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION MEDIATORS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES;

EID: 77954729885     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791320881     Document Type: Article

References (96)

1. Samuelsson B. The discovery of the leukotrienes. Am J Respir Crit Care Med 2000; 161: 2-6.
2. Woods JW, Evans JF, Ethier D, et al. 5-lipoxygenase and 5- lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. J Exp Med 1993; 178: 1935-46.
3. Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma. Pulm Pharmacol Ther 2001; 14: 3-19.
4. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006; 58: 375-88.
5. Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med 2004; 14: 191-5.
6. Wickelgren I. Gene suggests asthma drugs may ease cardiovascular inflammation. Science 2004; 303: 941.
7. Tager AM, Bromley SK, Medoff BD, et al. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol 2003; 4: 982-90.
8. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 2007; 27: 469-527.
9. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 123-34.
10. Harmar AJ, Hills RA, Rosser EM, et al. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucleic Acids Res 2009; 37: 680-5.
11. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G- protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387: 620-4.
12. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192: 421-32.
13. Yokomizo T, Kato T, Hagiya H, Izumi T, Shimizu Y. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem 2001; 276: 12454-9.
14. Lynch KR, Gary GP, O'neill P, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399: 789-93.
15. Sarau HM, Mong S, Foley JJ, Wu H-L, Crooke ST. Identification and characterization of leukotriene D4 receptors and signal transduction processes in rat basophilic leukemia cells. J Biol Chem 1987; 262: 4034-41.
16. Heise CE, O'Dowd BF, Figueroa DJ, et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 30531-6.
17. Takasaki J, Kamohara M, Matsumoto M, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun 2000; 274: 316-22.
18. Nothacker H-P, Wang Z, Zhu Y, Reinscheid RK, Lin SHS, Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 2000; 58: 1601-8.
19. Back M. Leukotriene receptors: crucial components in vascular inflammation. Sci World J 2007; 7: 1422-39.
20. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
21. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
22. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
23. Welch CL, Bretschger S, Latib N, et al. Localization of atherosclerosis susceptibility loci to chromosomes 4 and 6 using the Ldlr knockout mouse model. Proc Natl Acad Sci USA 2001; 98: 7946-51.
24. Mehrabian M, Wong J, Wang X, et al. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res 2001; 89: 125-30.
25. Mehrabian M, Allayee H, Wong J, et al. Identification of 5- lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002; 91: 120-6.
26. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-43.
27. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5- lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004; 350: 29-37.
28. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir H. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-9.
29. Helgadottir A, Gretarsdottir S, St Clair D, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005; 76: 505-9.
30. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38: 68-74.
31. Zhao L, Moos MP, Grabner R, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004; 10: 966-73.
32. Cao RY, St Amand T, Grabner R, Habenicht AJ, Funk CD. Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis 2009; 203: 395-400.
33. Ghazalpour A, Wang X, Lusis AJ, Mehrabian M. Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in mice. Genetics 2006; 173: 943-51.
34. De Caterina R, Zampolli A. From asthma to atherosclerosis--5- lipoxygenase, leukotrienes, and inflammation. N Engl J Med 2004; 350: 4-7.
35. Lotzer K, Funk CD, Habenicht AJ. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim Biophys Acta 2005; 1736: 30-7.
36. Radmark O, Samuelsson B. 5-lipoxygenase: regulation and possible involvement in atherosclerosis. Prostaglandins Other Lipid Mediat 2007; 83: 162-74.
37. Bäck M. Cysteinyl-leukotrienes in cerebrovascular disease: angels and demons? Arterioscler Thromb Vasc Biol 2008; 28: 805-6.
38. Iovannisci DM, Lammer EJ, Steiner L, et al. Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: the Muscatine Study. Arterioscler Thromb Vasc Biol 2007; 272: 394-9.
39. Bevan S, Dichgans M, Wiechmann HE, Gschwendtner A, Meitinger T, Markus HS. Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations. Stroke 2008; 39: 1109-14.
40. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599-1600.
41. Freiberg JJ, Tybjaerg-Hansen A, Sillesen H, Jensen GB, Nordestgaard BG. Promotor polymorphisms in leukotriene C4 synthase and risk of ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2008; 28: 990-6.
42. Freiberg JJ, Dahl M, Tybjaerg-Hansen A, Grande P, Nordestgaard BG. Leukotriene C4 synthase and ischemic cardiovascular disease and obstructive pulmonary disease in 13,000 individuals. J Mol Cell Cardiol 2009; 46: 579-865.
43. Bevan S, Lorenz MW, Sitzer M, Markus HS. Genetic variation in the leukotriene pathway and carotid intima-media thickness: a 2- stage replication study. Stroke 2009; 40: 696-701.
44. Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5- lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006; 103: 8161-6.
45. Jawien J. The putative role of leukotrienes in experimental atherogenesis. Pol Arch Med Wewn 2009; 119: 909-3.
46. Radmark O. 5-lipoxygenase-derived leukotrienes. Mediators also of atherosclerotic inflammation. Arterioscler Thromb Vasc Biol 2003; 23: 1140-2.
47. De Caterina R, Mazzone A, Giannessi D, et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed Biochim Acta 1988; 47: 182-5.
48. Lefebvre B, Pepin JL, Baguet JP, et al. Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur Respir J 2008; 32: 113-20.
49. Jawien J, Gajda M, Rudling M, et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 2006; 36: 141-6.
50. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002; 22: 443-9.
51. Subbarao K, Jala VR, Mathis S, et al. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol 2004; 24: 369-75.
52. Heller EA, Liu E, Tager AM, et al. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 2005; 112: 578-86.
53. Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 2005; 102: 17501-6.
54. Hlawaty H, Jacob MP, Louedec L, et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol 2009; 29: 518-24.
55. Kimand N, Luster AD. Regulation of immune cells by eicosanoid receptors. Sci World J 2007; 7: 1307-28.
56. Back M, Sultan A, Ovchinnikova O, Hansson GK. 5-Lipoxygenase- activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 100: 946-9 (2007).
57. Houard X, Ollivier V, Louedec L, Michel JB, Back M. Differential inflammatory activity across human abdominal aortic aneurysms reveals neutrophil-derived leukotriene B4 as a major chemotactic factor released from the intraluminal thrombus. FASEB J 2009; 23: 1376-83.
58. Cao RY, Adams MA, Habenicht AJ, Funk CD. Angiotensin II- induced abdominal aortic aneurysm occurs independently of the 5- lipoxygenase pathway in apolipoprotein E-deficient mice. Prostaglandins Other Lipid Mediat 2007; 84: 34-42.
59. Back M, Qiu H, Haeggstrom JZ, Sakata K. Leukotriene B4 is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor. Am J Physiol Heart Circ Physiol 2004; 287: 419-24.
60. Sakata K, Dahlen SE, Back M. The contractile action of leukotriene B4 in the guinea-pig lung involves a vascular component. Br J Pharmacol 2004; 141: 449-56.
61. Back M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med 2006; 38: 493-502.
62. Kuhn H, Anton M, Gerth C, et al. Amino acid differences in the deduced 5-lipoxygenase sequence of CAST atherosclerosis- resistance mice confer impaired activity when introduced into the human ortholog. Arterioscler Thromb Vasc Biol 2003; 23: 1072-6.
63. Back M, Hlawaty H, Labat C, Michel JB, Brink C. The oral cavity and age: a site of chronic inflammation? PLoS One 2007; 2: e1351.
64. Ahluwalia N, Lin AY, Tager AM, et al. Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol 2007; 179: 691-7.
65. Piomelli D, Feinmark SJ, Cannon PJ. Leukotriene biosynthesis by canine and human coronary arteries. J Pharmacol Exp Ther 1987; 241: 763-70.
66. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992; 85: 230-6.
67. Allen S, Sampson AP, Piper PJ, Chester AH, Ohri SK, Yacoub MH. Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery. Coron Artery Dis 1993; 4: 899-904.
68. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998; 97: 2406-13.
69. Back M, Airila-Mansson S, Jogestrand T, Soder B, Soder PO. Increased leukotriene concentrations in gingival crevicular fluid from subjects with periodontal disease and atherosclerosis. Atherosclerosis 2007; 193: 389-94.
70. Capra V, Ravasi S, Accomazzo MR, et al. CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensiti- zation: a possible feedback mechanism in inflammation. J Cell Sci 2005; 118: 5625-36.
71. Rovati GE, Capra V. Cysteinyl-leukotriene receptors and cellular signals. Sci World J 2007; 7: 1375-92.
72. Mellor EA, Maekawa A, Austen KF, Boyce JA. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Nat Acad USA 2001; 98: 7964-9.
73. Nonaka Y, Hiramoto H, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 2005; 337: 281-8.
74. Ciana P, Fumagalli M, Trincavelli ML, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl- leukotrienes receptor. EMBO J 2006; 25: 4615-27.
75. Jiang Y, Borrelli L, Bacskai BJ, Kanaoka Y, Boyce JA. P2Y6 receptors require an intact cysteinyl leukotriene synthetic and signaling system to induce survival and activation of mast cells. J Immunol 2009; 182: 1129-37.
76. Mamedova L, Capra V, Accomazzo MR, et al. CysLT(1) leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem Pharmacol 2005; 71: 115-25.
77. Mueller CF, Wassmann K, Widder JD, et al. Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation 2008; 117: 2912-8.
78. Sjostrom M, Johansson AS, Schroder O, Qiu H, Palmblad J, Haeggstrom JZ. Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 37-41.
79. Lotzer K, Spanbroek R, Hildner M, et al. Differential leukotriene receptor expression and calcium responses in endothelial cells and macrophages indicate5-lipoxygenase-dependent circuits of inflammation and atherogenesis. Arter Thromb Vasc Biol 2003; 23: 32-6.
80. Hui Y, Cheng Y, Smalera I, et al. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 2004; 110: 3360-6.
81. Pedersen KE, Bochner BS, Undem BJ. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non- CysLT1 receptor-mediated mechanism. J Pharmacol Exp Therap 1997; 281: 655-62.
82. Uzonyi B, Lotzer K, Jahn S, et al. Cysteinyl leukotriene 2 receptor and protease-activated receptor 1 activate strongly correlated early genes in human endothelial cells. Proc Natl Acad Sci USA 2006; 103: 6326-31.
83. Bäck M. Leukotriene receptors: crucial components in vascular inflammation. Sci World J 2007; 7: 1422-39.
84. Capra V, Ambrosio M, Riccioni G, Rovati GE. Cysteinyl- leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 2006; 13: 3213-26.
85. Back M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 2009; 23: 41-8.
86. Allayee H, Hartiala J, Lee W, et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest 2007; 132: 868-74.
87. Kaetsu Y, Yamamoto Y, Sugihara S, et al. Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro. Cardiovasc Res 2007; 76: 160-6.
88. Ge S, Zhou G, Cheng S, et al. Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model. Atherosclerosis 2009; 205: 74-9.
89. Mullane K, Hatala MA, Kraemer R, Sessa W, Westlin W. Myocardial salvage induced by REV-5901: an inhibitor and antagonist of the leukotrienes. J Cardiovasc Pharmacol 1987; 10: 398-406.
90. Hahn RA, MacDonald BR, Simpson PJ, et al. Characterization of LY233569 on 5-lipoxygenase and reperfusion injury of ischemic myocardium. J Pharmacol Exp Ther 1991; 256: 94-102.
91. Hock CE, Beck LD, Papa LA. Peptide leukotriene receptor antagonism in myocardial ischaemia and reperfusion. Cardiovasc Res 1992; 26: 1206-11.
92. Hahn RA, MacDonald BR, Morgan E, et al. Evaluation of LY203647 on cardiovascular leukotriene D4 receptors and myocardial reperfusion injury. J Pharmacol Exp Ther 1992; 260: 979-89.
93. Ito BR, Roth DM, Engler RL. Thromboxane A2 and peptidoleukotrienes contribute to the myocardial ischemia and contractile dysfunction in response to intracoronary infusion of complement C5a in pigs. Circ Res 1990; 66: 596-607.
94. Ito T, Toki Y, Hieda N, et al. Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart. Jpn Circ J 1989; 53: 1115-21.
95. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nature 2005; 4: 664-72.
96. Riccioni G, Capra V, D'Orazio N, Bucciarelli T, Bazzano LA. Leukotriene modifiers in the treatment of cardiovascular diseases. J Leukoc Biol 2008; 84: 1374-8.